Recent Updates in the Management of Lower-Risk Myelodysplastic Syndrome

home / precision-medicine-perspectives / recent-updates-in-the-management-of-lower-risk-myelodysplastic-syndrome

This series comprised of videos and articles explores recent updates in the management of lower-risk myelodysplastic syndrome.

Elias Jabbour, MD, an expert on myelodysplastic syndrome

EP. 1: Overview of Myelodysplastic Syndrome

Elias Jabbour, MD
June 29th 2023

In the first installment of this series, Elias Jabbour, MD, provides an overview of myelodysplastic syndrome, discusses the current treatment landscape for lower-risk MDS, and offers insights on factors that influence treatment selection.

Elias Jabbour, MD, an expert on myelodysplastic syndrome

EP. 2: Clinical Insights on Treating Myelodysplastic Syndrome

Elias Jabbour, MD
June 30th 2023

In the first article of this series, Elias Jabbour, MD, gives an overview of myelodysplastic syndrome and discusses the evolving treatment landscape.

Abdulraheem Yacoub, MD, an expert on myelodysplastic syndrome

EP. 3: IMerge Trial: Key Efficacy Outcomes

Abdulraheem Yacoub, MD
August 2nd 2023

Following the 2023 ASCO Annual Meeting, Abdulraheem Yacoub, MD, reviews key data updates from the IMerge trial investigating imetelstat in patients with lower-risk MDS.

Abdulraheem Yacoub, MD, an expert on myelodysplastic syndrome

EP. 4: Data Updates From the IMerge Trial

Abdulraheem Yacoub, MD
August 14th 2023

In the second article of this series, Abdulraheem Yacoub, MD, discusses recent updates from the IMerge clinical trial, which is studying imetelstat in patients with low-risk MDS.

Eytan M. Stein, MD, an expert on myelodysplastic syndrome

EP. 5: Follow-Up Efficacy Data of Imetelstat in Lower-Risk MDS

Eytan M. Stein, MD
September 1st 2023

Eytan M. Stein, MD, reviews recent follow-up data from the IMerge trial investigating imetelstat in patients with lower-risk myelodysplastic syndrome.

Eytan M. Stein, MD, an expert on myelodysplastic syndrome

EP. 6: Evolving Treatment Landscape in Lower-Risk MDS

Eytan M. Stein, MD
September 8th 2023

In the third article of this series, Eytan M. Stein, MD, discusses the treatment landscape for patients with lower-risk MDS and reviews follow-up data from the IMerge clinical trial.

Site Logo

EP. 7: Safety Outcomes for Imetelstat in Lower-Risk MDS

September 25th 2023
Amer Zeidan, MBBS, MHS, an expert on myelodysplastic syndrome

EP. 8: Updates in the Management of Lower-Risk MDS

Amer Zeidan, MBBS
October 13th 2023

Amer Zeidan, MBBS, MHS, reviews recent luspatercept and imetelstat data from the COMMANDS and IMerge clinical trials in lower-risk myelodysplastic syndrome.

Amer Zeidan, MBBS, MHS, an expert on myelodysplastic syndrome

EP. 9: Recent Updates in Lower-Risk MDS

Amer Zeidan, MBBS
November 2nd 2023

In the fourth article of this series, Amer Zeidan, MBBS, MHS, reviews recent data in lower-risk myelodysplastic syndrome and discusses the evolving treatment landscape.

Yazan Madanat, MD, an expert on myelodysplastic syndromes

EP. 10: Updates in Lower-Risk MDS: Imetelstat

Yazan Madanat, MD
December 22nd 2023

Yazan Madanat, MD, comments on the updates that were recently presented at ASH 2023 for the management of lower-risk MDS and discusses the impact of emerging therapies.

Yazan Madanat, MD, an expert on MDS

EP. 11: Key Updates in Lower-Risk MDS

Yazan Madanat, MD
February 5th 2024

In the fifth article of this series, Yazan Madanat, MD, reviews recent updates presented at the 2023 ASH Annual Meeting and discusses the evolving treatment landscape.